Iovance Biotherapeutics
IOVA
$13.45
Share price
0.45%
Change (1 day)
89.97%
Change (1 year)
Categories
Iovance Biotherapeutics (IOVA) - P/B ratio
P/B ratio as of May 2024 : 6.41
According to Iovance Biotherapeutics
's latest financial reports the company has a price-to-book ratio of 6.41.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Iovance Biotherapeutics - P/B ratio (from 2010 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 3.56 | 76.35% |
| 2022-12-31 | 2.02 | -58.11% |
| 2021-12-31 | 4.82 | -53.53% |
| 2020-12-31 | 10.4 | -11.42% |
| 2019-12-31 | 11.7 | 399.55% |
| 2018-12-31 | 2.34 | -41.34% |
| 2017-12-31 | 3.99 | 54.22% |
| 2016-12-31 | 2.59 | -28.12% |
| 2015-12-31 | 3.60 | -39.17% |
| 2014-12-31 | 5.92 | -50.41% |
| 2013-12-31 | 11.9 | -854.28% |
| 2012-12-31 | -1.58 | -74.38% |
| 2011-12-31 | -6.18 | -104.46% |
| 2010-12-31 | 138 | |
| 2009-12-31 | N/A | |
| 2008-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Nymox Pharmaceutical NYMX | -6.34 | -198.99% | Bahamas |
 NRC Health
NRC | 14.5 | 126.42% | 🇺🇸 USA |